Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)

Summary

This study will assess the efficacy, safety and pharmacodynamic markers of the study drug, A6, in patients with CLL and small lymphocytic lymphoma (SLL).

Timeline

Start

2014-02

Primary completion

2015-11

Completion

2016-03

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment”

Drugs

Indications